Keryx Biopharmaceuticals trades as part of the biotechnology industry and is part of the healthcare sector. The company CEO is Jodie P. Morrison. Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.



Previous Intraday Performance:

The KERX shares had a previous change of -2.04% which opened at 3.44 and closed at 3.36. It moved to an intraday high of 3.47 and a low of 2.97.

SeekingAlpha:  Akebia Therapeutics and Keryx Biopharmaceuticals complete merger

Historical Performance:

Over the last five trading days, KERX shares returned 5.99% and in the past 30 trading days it returned 17.07%. Over three months, it changed 12.00%. In one year it has changed -26.32% and within that year its 52 week high was 5.98 and its 52 week low was 2.47. KERX stock is 36.03% above its 52 week low.

Our calculations result in a 200 day moving average of 3.98 and a 50 day moving average of 3.04. Right now, KERX stock is trading -15.58% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Akebia Therapeutics and Keryx Biopharmaceuticals complete merger

Liquidity:

The company has a market cap of $404.5m with 120.4m shares outstanding and a float of 112.8m shares. Trading volume was 2,587,932 shares and has experienced an average volume of 1,549,156 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Keryx Biopharmaceuticals was -1.43 which ended on 31st of December 2017. Based on 3 analyst estimates, the consensus EPS for the next quarter is -0.13.

Below was the last reported quarterly diluted earnings per share:

3rdQtr 2018Reported 11-08-2018: -0.14
2ndQtr 2018Reported 08-08-2018: -0.18
1stQtr 2018Reported 05-10-2018: -0.18
4thQtr 2017Reported 02-07-2018: -0.25
3rdQtr 2017Reported 11-07-2017: -0.20

EPS growth is an important number as it indicates the future prospects of Keryx Biopharmaceuticals; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 59.70% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 6.30% of insider ownership and 75.40% of institutional ownership.



The beta was calculated to be 2.17.

PR Newswire:  HRTX Class Action Alert: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Heron Therapeutics, Inc. — HRTX

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -55.80%, profit margin is -96.41%, price-to-sales is 4.38 and price-to-book is 61.58.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 1  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here